Search

Displaying results 1311 - 1320 of 8696 in total
  1. Drug

    Tyrothricin

    go.drugbank.com/drugs/DB13503
    ApprovedWithdrawn

    Moreover, tyrothricin possesses broad spectrum Gram-positive antibacterial and antifungal activity that has not seen many - if any - significant reportings of microbial resistance during the over 60 years … Nevertheless, as tyrothricin is both cytolytic and hemolytic, it does demonstrate systemic toxicity [L4019, L4021, L4022], although certain formulations that are safe for human use like throat lozenges

    Categories: Antibiotics for Topical Use
  2. Drug

    ISIS 113715

    go.drugbank.com/drugs/DB05506
    Investigational

    ISIS 113715 is our second-generation antisense inhibitor of protein tyrosine phosphatase 1b, or PTP‑1b, for the treatment of type 2 diabetes.

  3. Drug

    Abametapir

    go.drugbank.com/drugs/DB11932
    Approved

    The necessity for follow-up treatment may lead to challenges with patient adherence, and resistance to agents like permethrin and [pyrethrins]/[piperonyl butoxide] may be significant in some areas. … The improved ovicidal activity (90-100% _in vitro_) of abemetapir allows for a single administration, in contrast to many other topical treatments, and its novel and relatively non-specific mechanism may

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Inhibitors
  4. Drug

    Butabarbital

    go.drugbank.com/drugs/DB00237
    ApprovedIllicitWithdrawn

    [A201977,L13613] Butabarbital is less commonly used in recent years, as more patients are typically prescribed benzodiazepines. … [A201977,L13613] This makes butabarbital a useful drug for treating severe insomnia and pre-operative anxiety.

  5. Drug

    Camizestrant

    go.drugbank.com/drugs/DB19218
    ApprovedInvestigational

    [L64094,L64107] Patients are selected for treatment on the basis of an *ESR1* mutation detected by circulating tumor DNA testing during first-line endocrine therapy, before radiographic disease progression … Camizestrant is an oral selective estrogen receptor degrader (SERD) and estrogen receptor (ER) antagonist used in combination with a CDK4/6 inhibitor to treat hormone receptor-positive, HER2-negative locally

    Categories: Estrogen Receptor Antagonists, Selective Estrogen Receptor Degraders
  6. Drug

    Colestipol

    go.drugbank.com/drugs/DB00375
    Approved

    [FDA Label, F4555, F4567, L6262] And even though such an agent may very well be useful in reducing elevated cholesterol levels and decreasing the risk for atherosclerotic vascular disease due to hypercholesterolemia … not be good candidates for using the agent owing to its physical effects on the gut.

    Categories: Hypolipidemic Agents Indicated for Hyperlipidemia, Non-statin Hypolipidemic Agents Indicated for Hyperlipidemia
  7. Drug

    Encainide

    go.drugbank.com/drugs/DB01228
    ApprovedWithdrawn

    Encainide hydrochloride, formerly marketed as Enkaid capsules, was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a recent heart attack.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesSynonyms: (±)-2'-[2-(1-methyl-2-piperidyl)ethyl]-p-anisanilide
  8. Drug

    Atoltivimab

    go.drugbank.com/drugs/DB15898
    ApprovedInvestigational

    [A221825, A221830] A recent large-scale study elucidated that both neutralizing and Fc-mediated functions of antibodies were important for therapeutic benefit in animal models of EBOV infection. … Ebola virus (EBOV) remains an important human pathogen within the _Ebolavirus_ genus, having been responsible for at least 17 known outbreaks with an average case fatality rate of 43.92%.

    Categories: Treatments for Ebola Virus Disease
  9. Drug

    Stem bromelain

    go.drugbank.com/drugs/DB12249
    Approved

    Bromelain is consequently a composite mixture of several different endopeptidases that can facilitate many different reactions with many different substrates. … The primary therapeutic use for which stem bromelain is currently and formally indicated is as a burn wound eschar debridement agent that has been approved by the EMA since 2012 and marketed under the

  10. Drug

    Tizanidine

    go.drugbank.com/drugs/DB00697
    ApprovedInvestigational

    Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury [T574]. … It may also be caused by musculoskeletal injury [A177583]. Regardless of the cause, muscle spasticity can be an extremely painful and debilitating condition.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates